Theratechnologies Inc.
THTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$155.87M
Close$
$1.77
47.6% downside
Current Fair Value
47.6% downsideOvervalued by 47.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $155.87 Million |
|---|---|
| Enterprise Value | $190.28 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.17 |
| Beta | 0.81 |
| Outstanding Shares | 49,361,835 |
Return
| Return on Equity | 32.79% |
|---|---|
| Return on Assets | -17.86% |
| Return on Invested Capital | 1.58% |
Valuation & Multiples
| P/E Ratio | -36.31 |
|---|---|
| PEG | 6.58 |
| Price to Sales | 3.39 |
| Price to Book Ratio | -3.39 |
| Enterprise Value to Revenue | 2.26 |
| Enterprise Value to EBIT | 993.62 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | -1.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.53%▼ 20.65% |
|---|---|
| Total Invested | $5.90M▼ 79.06% |
| Investors Holding | 10▼ 39.00% |
ESG Score
No data
About Theratechnologies Inc.
CEO: Paul Levesque Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.